Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
CervicalOvarianLungBreastRenal
Interventions
DRUG

paclitaxel

Paclitaxel 135 mg/m\^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.

DRUG

CBT-1(Registered Trademark)

CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.

RADIATION

Tc 99m sestamibi

20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00972205 - Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors | Biotech Hunter | Biotech Hunter